333 related articles for article (PubMed ID: 37012629)
21. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
[TBL] [Abstract][Full Text] [Related]
22. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
[TBL] [Abstract][Full Text] [Related]
23. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
Papamichael K; Jairath V; Zou G; Cohen B; Ritter T; Sands B; Siegel C; Valentine J; Smith M; Vande Casteele N; Dubinsky M; Cheifetz A
BMJ Open; 2022 Apr; 12(4):e057656. PubMed ID: 35365535
[TBL] [Abstract][Full Text] [Related]
24. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Alsoud D; Moes DJAR; Wang Z; Soenen R; Layegh Z; Barclay M; Mizuno T; Minichmayr IK; Keizer RJ; Wicha SG; Wolbink G; Lambert J; Vermeire S; de Vries A; Papamichael K; Padullés-Zamora N; Dreesen E
Ther Drug Monit; 2024 Jun; 46(3):291-308. PubMed ID: 38648666
[TBL] [Abstract][Full Text] [Related]
25. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
28. INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE.
Queiroz NSF; Teixeira FV; Parra RS; Kotze PG
Arq Gastroenterol; 2020; 57(4):507-510. PubMed ID: 33331484
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis.
Manceñido Marcos N; Novella Arribas B; Mora Navarro G; Rodríguez Salvanés F; Loeches Belinchón P; Gisbert JP
Dig Liver Dis; 2024 Mar; 56(3):421-428. PubMed ID: 37422409
[TBL] [Abstract][Full Text] [Related]
30. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
Hoseyni H; Xu Y; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
Mitrev N; Leong RW
Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
[TBL] [Abstract][Full Text] [Related]
34. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.
Sánchez-Hernández JG; Rebollo N; Martin-Suarez A; Calvo MV; Muñoz F
Br J Clin Pharmacol; 2020 Jun; 86(6):1165-1175. PubMed ID: 32022291
[TBL] [Abstract][Full Text] [Related]
35. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
36. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease.
Díaz LS; Navalón CI; Espín RG; Prado IN; Redondo LR
Gastroenterol Hepatol; 2023; 46(7):504-511. PubMed ID: 36400260
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.
van Hoeve K; Hoffman I; Vermeire S
Expert Opin Drug Saf; 2018 Feb; 17(2):185-196. PubMed ID: 29202588
[TBL] [Abstract][Full Text] [Related]
38. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Cheifetz AS; Abreu MT; Afif W; Cross RK; Dubinsky MC; Loftus EV; Osterman MT; Saroufim A; Siegel CA; Yarur AJ; Melmed GY; Papamichael K
Am J Gastroenterol; 2021 Oct; 116(10):2014-2025. PubMed ID: 34388143
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.
Deora V; Kozak J; El-Kalla M; Huynh HQ; El-Matary W
Acta Paediatr; 2017 Nov; 106(11):1863-1867. PubMed ID: 28779489
[TBL] [Abstract][Full Text] [Related]
40. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Samaan MA; Arkir Z; Ahmad T; Irving PM
Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
